Clinical trials targeting angiogenesis and ECM components in AML, such as those focusing on VEGF inhibitors and matrix metalloproteinase inhibitors, could benefit from incorporating BMG profiling to stratify patient subgroups and optimize therapeutic outcomes 53. This evidence concerns the gene VEGFA and acute myeloid leukemia.